Bimekizumab Long-Term Safety and Efficacy Across the Spectrum of Axial Spondyloarthritis Over 3 Years: Results From 2 Phase III Studies.
J RheumatolOct 1, 2026 (epub)
Clinical ResearchRheumatology
Xenofon Baraliakos, Atul Deodhar, Désirée van der Heijde et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the long-term safety and efficacy of bimekizumab, an IL-17A and IL-17F inhibitor, in patients with axial spondyloarthritis over 3 years. In a multicenter, randomized controlled trial involving patients from two phase III studies, 57.0% achieved low disease activity at week 164, with no new safety signals reported.
Key findings
- 90.4% of patients experienced at least one treatment-emergent adverse event during the study.
- The exposure-adjusted incidence rate for fungal infections was 9.4 per 100 patient-years.
- 57.0% of patients achieved low disease activity at week 164, with 28.7% achieving inactive disease.
- Sustained improvements in BASFI and quality of life scores were observed through week 164.
Why it matters
Understanding the long-term safety and efficacy of bimekizumab is crucial for clinicians managing axial spondyloarthritis, as it informs treatment decisions and patient expectations regarding disease control and quality of life.